Literature DB >> 7003264

Characterization of melanoma cell membrane tumor-associated antigens using xenoserum, alloserum, and autoserum: I. immunofluorescence.

P A Mutzner, G M Stuhlmiller, H F Seigler.   

Abstract

Xenoantiserum, alloantiserum, and autoantiserum prepared against human melanoma cells from cell lines maintained in tissue culture were evaluated by indirect immunofluorescence (ind IF) for their content of antibodies reactive with melanoma cell membrane tumor-associated antigens (TAA). Following absorptions which removed all detectable anti-human species, anti-RBC, and anti-HLA antigen activity, the antisera were tested against a panel of human cell lines. Three apparently distinct melanoma-associated cell membrane antigens were detected. The first of these was present on all human cells maintained in tissue culture including cells of both malignant and nonmalignant origin. The second antigen was expressed on all cells of malignant origin and also by fetal fibroblasts. The third antigen was detectable only on melanoma cells and was expressed by a majority of the melanomas tested. No evidence was obtained to suggest the presence of melanoma TAA unique to a single melanoma cell line. Marked differences were observed in the antigenic profile detected by the three antisera.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7003264     DOI: 10.1002/jso.2930140411

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  2 in total

1.  Serological response of non-human primates to human melanoma disialoganglioside GD3.

Authors:  G M Stuhlmiller; K M Roberson; H F Seigler
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  In vivo tumor localization using tumor-specific monkey xenoantibody, alloantibody, and murine monoclonal xenoantibody.

Authors:  G M Stuhlmiller; D C Sullivan; C E Vervaert; B P Croker; C C Harris; H F Seigler
Journal:  Ann Surg       Date:  1981-11       Impact factor: 12.969

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.